Publications by authors named "Michelle M Berrey"

Claim this Profile
S
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Eric Lawitz, Jay P Lalezari, Tarek Hassanein, Kris V Kowdley, Fred F Poordad, Michelle M Berrey

Lancet Infect Dis· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
Maribel Rodriguez-Torres, Eric Lawitz, Kris V Kowdley, David R Nelson, Edwin Dejesus, Michelle M Berrey

J Hepatol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.
Jill Denning, Melanie Cornpropst, Stephen D Flach, Michelle M Berrey, William T Symonds

Antimicrob Agents Chemother· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.
Eric Lawitz, Maribel Rodriguez-Torres, Jill M Denning, Efsevia Albanis, Melanie Cornpropst, Michelle M Berrey

Antimicrob Agents Chemother· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection.
Ian R White, Keyur Patel, William T Symonds, Anouk Dev, Philip Griffin, Michelle M Berrey

J Transl Med· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis